Abstract CT129: Phase II clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in NSCLC involving the CNS

@article{Weiner2016AbstractCP,
  title={Abstract CT129: Phase II clinical trial results for 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in NSCLC involving the CNS},
  author={R. Weiner and T. Mahmood and Craig Gordon and M. Ware and L. Morgan and Tm Cosgriff and A. H. Rodgers and G. Bastian and R. Kawauchi and M. Matrana and J-J Zou},
  journal={Cancer Research},
  year={2016},
  volume={76}
}
  • R. Weiner, T. Mahmood, +8 authors J-J Zou
  • Published 2016
  • Medicine
  • Cancer Research
  • Background: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a poly-chlorinated pyridine cholesteryl carbonate with a MOA via bis-alkylation of DNA @ N7-guanine and N4-cytosine that has completed a Phase I study [AACR #1185, 2013] and is being evaluated in a Phase II trial in patients with primary brain cancers and with melanoma, breast, and lung cancers with metastases to brain. The aims are to assess clinical response when DM-CHOC-PEN is administered I.V. at MTD and to monitor… CONTINUE READING